In an effort to develop a firmer understanding of the genomic landscape that characterizes the development and progression of squamous cell lung cancer, investigators conducted a detailed qualitative ...
Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...
Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...
This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn. Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results ...
Population Relevance, Histology, and PD-L1 Considerations, our panel delve into the following critical questions: Is the ...
Camrelizumab plus chemotherapy doubled the five-year survival rate in advanced squamous lung cancer to 27.8%, reducing mortality risk by 43%. The CameL-sq trial demonstrated camrelizumab's efficacy as ...
CHAF1B, a histone chaperone component of the chromatin assembly factor-1 complex, is overexpressed in multiple cancers and linked to tumor progression, but its role in lung squamous-cell carcinoma ...
CHAF1B, a histone chaperone component of the chromatin assembly factor-1 complex, is overexpressed in multiple cancers and linked to tumor progression, but its role in lung squamous-cell carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results